MYC and pancreatic adenocarcinoma: To address whether Myc hypomorphism imposed after KRasG12D activation also suppresses progression of precancerous lesions, we used the well-characterised LSL-KRasG12D/+;LSL-p53R172H/+;pdx1-Cre; (KPC) mouse model of pancreatic adenocarcinoma (PDAC)46.